• SRX Global entered a deal to buy all shares of CERo Therapeutics, a wholly owned operating unit of CERo Therapeutics Holdings.
• Consideration includes $1 million in SRX common stock, priced off the lower of prior close or 20-day VWAP.
• SRX will cancel a Consolidated Senior Secured Promissory Note up to $11,666,108.77; outstanding principal was $8,249,643.77.
• Assumed liabilities are about $1.56 million, with SRX providing indemnities tied to those assumed obligations.
• A 30-day go-shop allows Holdings to seek alternatives; a superior bid must close by March 15, 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SRX Global Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-046085), on October 07, 2026, and is solely responsible for the information contained therein.